Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Programs at the European Hematology Association Annual Meeting
Published on June 05, 2015
June 4, 2015 – New York (USA) – Cellectis (Alternext: ALCLS – Nasdaq Global Market: CLLS), the gene-editing company employing proprietary technologies to develop best-in-class CAR T-cell products in adoptive immunotherapy for cancer, today announced that pre-clinical data on its engineered allogeneic CAR T-cells will be featured in two oral presentations and one poster presentation at the European Hematology Association (EHA) Annual Meeting. The meeting will be held from June 11th to 14th, 2015, in Vienna, Austria.
The selected presentations are as follow:
- Allogeneic adoptive immunotherapy of acute myeloid leukemia (ALM) by targeting CD123 with CAR T-Cells
Oral Presentation
Session Title: Gene therapy, cellular immunotherapy & vaccination
Presentation Time: Saturday, June 13th, 2015, 12:15pm to 12:30pm
- UCART19, an Allogeneic “Off-the-Shelf” Adoptive T-Cell Immunotherapy Against CD19+ B-Cell Leukemias
Oral Presentation
Session Title: Gene therapy, cellular immunotherapy & vaccination
Presentation Time: Saturday, June 13th, 2015, 12:30pm to 12:45pm
- Adoptive immunotherapy of multiple myeloma (MM) with allogeneic CAR T-Cells targeting CS1: enhancement of CAR activity through CS1 gene inactivation in effector cells
Poster Presentation
Session Title: Gene therapy, cellular immunotherapy & vaccination Presentation Time: Saturday, June 13th, 2015, 5:15pm to 6:45pm